Alvotech (ALVO) Competitors $8.12 +0.09 (+1.12%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$8.15 +0.03 (+0.37%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVO vs. MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, RYTM, LEGN, ABVX, and RNAShould you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Alvotech vs. Its Competitors Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Moderna (NASDAQ:MRNA) and Alvotech (NASDAQ:ALVO) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Which has better earnings and valuation, MRNA or ALVO? Alvotech has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.06B3.04-$3.56B-$7.53-3.17Alvotech$491.98M4.98-$231.86M$0.2335.30 Is MRNA or ALVO more profitable? Alvotech has a net margin of 11.26% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% Alvotech 11.26%-38.36%9.28% Do analysts prefer MRNA or ALVO? Moderna presently has a consensus target price of $41.81, suggesting a potential upside of 75.09%. Alvotech has a consensus target price of $14.00, suggesting a potential upside of 72.41%. Given Moderna's higher possible upside, equities research analysts clearly believe Moderna is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.05Alvotech 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals hold more shares of MRNA or ALVO? 75.3% of Moderna shares are held by institutional investors. 11.0% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor MRNA or ALVO? In the previous week, Moderna had 16 more articles in the media than Alvotech. MarketBeat recorded 19 mentions for Moderna and 3 mentions for Alvotech. Alvotech's average media sentiment score of 1.24 beat Moderna's score of 0.59 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 6 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, MRNA or ALVO? Moderna has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. SummaryModerna beats Alvotech on 9 of the 17 factors compared between the two stocks. Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVO vs. The Competition Export to ExcelMetricAlvotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.42B$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio35.3021.2475.0826.39Price / Sales4.98420.70508.41175.01Price / CashN/A44.4425.8129.91Price / Book-5.939.6413.596.28Net Income-$231.86M-$53.20M$3.29B$270.38M7 Day Performance0.12%0.07%0.07%1.89%1 Month Performance1.25%4.27%4.57%6.01%1 Year Performance-25.37%9.62%76.79%25.26% Alvotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVOAlvotech3.7617 of 5 stars$8.12+1.1%$14.00+72.4%-24.9%$2.42B$491.98M35.301,032Short Interest ↓MRNAModerna4.4726 of 5 stars$24.83-1.2%$42.88+72.7%-65.0%$9.78B$3.24B-3.305,800VRNAVerona Pharma PLC American Depositary Share2.3188 of 5 stars$106.300.0%$109.00+2.5%+257.2%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.6343 of 5 stars$19.02+3.2%$17.33-8.9%+28.7%$9.16B$4.44B22.129,000Positive NewsROIVRoivant Sciences3.1585 of 5 stars$12.91-0.1%$16.38+26.8%+16.8%$8.82B$29.05M-18.44860RVMDRevolution Medicines4.191 of 5 stars$41.06+1.4%$72.00+75.4%+5.7%$7.57B$11.58M-9.12250Insider TradeAnalyst RevisionGRFSGrifols3.9957 of 5 stars$10.11-0.2%$10.30+1.9%+4.0%$6.96B$7.81B8.6423,822RYTMRhythm Pharmaceuticals3.2887 of 5 stars$99.77-2.3%$101.57+1.8%+93.5%$6.78B$130.13M-33.15140Positive NewsLEGNLegend Biotech3.2015 of 5 stars$34.62-4.0%$74.22+114.4%-32.7%$6.66B$627.24M-39.342,609Positive NewsABVXAbivax2.3952 of 5 stars$90.00+2.2%$92.33+2.6%+632.7%$6.65BN/A0.0061Analyst UpgradeShort Interest ↑Gap DownRNAAvidity Biosciences2.1127 of 5 stars$48.05-4.6%$67.00+39.4%-3.6%$6.48B$10.73M-13.50190Analyst Forecast Related Companies and Tools Related Companies MRNA Competitors VRNA Competitors ELAN Competitors ROIV Competitors RVMD Competitors GRFS Competitors RYTM Competitors LEGN Competitors ABVX Competitors RNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVO) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALVO Stock Alerts